NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
KIMS Q3 FY26: Revenue Crosses ₹1,000 Cr Milestone; Margins Contract to 20.4% on New Unit Drags
KIMS reported a record-breaking quarter with total revenue crossing ₹1,003 crores, a 29.2% YoY increase driven by aggressive expansion. However, consolidated PAT declined significantly to ₹52 crores from ₹93 crores YoY, primarily due to gestation losses from seven new hospitals launched in 2025. Management expects the Thane and Bangalore units to reach EBITDA neutrality by Q1 FY27, which should trigger margin recovery. Operational metrics remain robust with ARPOB growing 20.5% YoY, supported by high-value transplant procedures in new clusters.
முக்கிய அம்சங்கள்
Total revenue reached ₹1,003 crores, marking a 29.2% YoY growth and crossing the ₹1,000 Cr quarterly mark for the first time.EBITDA margins compressed to 20.4% from 25.9% YoY due to operational costs of 7 new units launched across 5 states.Average Revenue Per Operating Bed (ARPOB) grew by 20.5% YoY, significantly aided by 25 transplants in the new Bangalore unit.Consolidated PAT fell 44% YoY to ₹52 crores, resulting in a diluted EPS of ₹1.3 compared to ₹2.16 in the previous year.Andhra cluster volumes were temporarily impacted by a one-month strike related to the Aarogyasri scheme, though recovery was noted in January.
👀 கவனிக்க வேண்டியவை
Investors should focus on the EBITDA break-even trajectory of the new Bangalore and Thane units over the next two quarters. While the current PAT decline reflects heavy expansion costs, the strong ARPOB growth suggests high-quality asset utilization that could drive significant operating leverage once units stabilize.
KIMS Reports FY25 Revenue of ₹3,067 Cr and Expands Network to 18 Hospitals
KIMS released its Q3 and 9M FY26 investor presentation, highlighting a strong growth trajectory with total revenue reaching ₹3,067 crore in FY25. The hospital network expanded significantly from 12 units in 2024 to 18 units in 2025, reflecting aggressive geographic expansion across South and West India. EBITDA grew to ₹759 crore in FY25, maintaining a robust long-term CAGR of 29.7%. The company is targeting a total bed capacity of over 9,100 beds through upcoming projects in locations like Kompally and Gachibowli.
முக்கிய அம்சங்கள்
Total revenue grew to ₹30,670 million in FY25, representing a 26.9% CAGR since 2005EBITDA reached ₹7,590 million in FY25 with a healthy long-term CAGR of 29.7%Hospital network expanded from 12 to 18 units within a single year between 2024 and 2025Future roadmap targets a massive capacity of 9,100+ beds across Telangana, AP, Maharashtra, and KeralaStrong institutional backing with DIIs and FIIs holding a combined 49.3% stake as of December 2025
👀 கவனிக்க வேண்டியவை
Investors should monitor the operational ramp-up and occupancy levels of the 6 newly added hospitals, as they will be the primary drivers for revenue growth in FY26-27. The company's consistent 29%+ EBITDA CAGR makes it a high-quality growth play in the healthcare sector.
KIMS Q3 FY26: Revenue Crosses ₹1,000 Cr Milestone; PAT Drops 44% YoY to ₹52 Cr
KIMS reported a strong 26.9% YoY revenue growth, crossing the ₹1,000 crore quarterly milestone for the first time. However, profitability was significantly impacted by the operationalization of new units, with PAT declining 44% YoY to ₹52 crore and EBITDA margins contracting to 20.4% from 25.9%. Operational metrics remained robust as ARPOB grew by 20.5% YoY, indicating better realization per bed. The management remains optimistic as new units in Bangalore and Thane continue to ramp up clinical and non-clinical parameters.
முக்கிய அம்சங்கள்
Total Revenue reached ₹1,003 Cr, growing 26.9% YoY and 3.9% QoQ.PAT declined to ₹52 Cr from ₹93 Cr in the previous year, a 44% drop.EBITDA margins compressed to 20.4% compared to 25.9% in Q3 FY25 due to costs from newer units.ARPOB (Average Revenue Per Occupied Bed) showed strong growth of 20.5% YoY.The group currently operates 7,100+ beds with plans to expand to 9,100+ beds.
👀 கவனிக்க வேண்டியவை
Investors should monitor the break-even timeline for the new units in Bangalore and Thane, as their current drag on margins is the primary concern. The strong top-line growth and ARPOB improvement suggest healthy underlying demand, making this a long-term play once margins stabilize.
KIMS to Invest ₹100 Crore to Increase Stake in Subsidiary Sunshine Hospital
The Board of KIMS has approved an additional investment of up to ₹100 Crores to acquire further shares in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake in the subsidiary, which has shown strong financial performance with turnover growing from ₹419.44 Cr in FY23 to ₹597.00 Cr in FY25. The acquisition will be executed in one or more tranches from minority shareholders via cash consideration. This strategic move aims to consolidate ownership in a key performing asset specializing in orthopedics and high-end healthcare.
முக்கிய அம்சங்கள்
Board approved ₹100 Crore investment to buy out minority shareholders in Sunshine Hospital.Sunshine Hospital turnover grew 28.6% year-on-year to ₹597.00 Cr in FY25.KIMS currently owns 75.53% of the subsidiary and seeks to further enhance this shareholding.The acquisition will be funded through cash based on independent valuation reports.Sunshine Hospital is a key asset for KIMS, focusing on high-growth segments like orthopedics and transplants.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive consolidation of a high-growth subsidiary. Monitor the final acquisition price and the resulting impact on consolidated net profit margins.
KIMS Shareholders Approve Material RPT with Bengaluru Subsidiary with 93.18% Majority
Krishna Institute of Medical Sciences (KIMS) has successfully passed a resolution via postal ballot to approve a material related party transaction with its subsidiary, KIMS Hospital Bengaluru Private Limited. The resolution received 93.18% support from the total votes polled, ensuring the company can proceed with its internal financial and operational arrangements. While promoters and non-institutional public shareholders showed near-unanimous support, approximately 12.75% of institutional votes were cast against the proposal. This approval is a necessary step for the company's integrated operations and expansion in the Bengaluru region.
முக்கிய அம்சங்கள்
Resolution for Material Related Party Transaction with KIMS Hospital Bengaluru Private Limited passed with 93.18% majority.Total of 31.85 crore votes were polled, representing a 79.61% turnout of the total shareholding.Public institutional investors cast 2.17 crore votes (12.75% of their category) against the resolution.Promoter group and non-institutional public shareholders voted nearly 100% in favor of the transaction.The resolution is deemed passed as of February 01, 2026, the final date of e-voting.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step for operational synergy within the group's Bengaluru expansion. While the institutional dissent is minor, it is worth monitoring future related party disclosures for specific financial terms.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
KIMS Seeks Shareholder Approval for ₹150 Cr Related Party Transaction with Bengaluru Subsidiary
Krishna Institute of Medical Sciences (KIMS) has issued a postal ballot notice to seek shareholder approval for material related party transactions with its subsidiary, KIMS Hospital Bengaluru Private Limited (KHBPL). The resolution proposes an aggregate transaction limit of up to ₹150 Crores, covering both existing and new contracts, including loans, until the Annual General Meeting in FY 2026-27. The company maintains that these transactions will be conducted at arm's length and in the ordinary course of business. Shareholders can participate in the remote e-voting process from January 3, 2026, to February 1, 2026.
முக்கிய அம்சங்கள்
Proposed aggregate value for transactions with KIMS Hospital Bengaluru Private Limited is up to ₹150 Crores.The approval covers transactions and loans to be entered into until the AGM of Financial Year 2026-27.Cut-off date for determining member eligibility for e-voting was December 30, 2025.E-voting period spans 30 days, concluding on February 1, 2026, at 5:00 PM IST.
👀 கவனிக்க வேண்டியவை
Investors should monitor the capital allocation to the Bengaluru subsidiary to ensure it translates into regional growth and improved consolidated margins. This is a standard regulatory requirement for material transactions with subsidiaries.
KIMS to Enter Tamil Nadu with 300-Bed Super Speciality Hospital in Chennai for Rs 300 Cr
Krishna Institute of Medical Sciences (KIMS) has signed a long-term lease agreement for 1.168 acres of land in Chennai to establish its first hospital in Tamil Nadu. The project involves setting up a 300-bed super speciality facility with an estimated investment of Rs 300 crore. This expansion is slated for completion within the next 36 months and will be funded through a mix of internal accruals and bank loans. As of September 2025, the company operates over 8,800 beds with an occupancy rate of approximately 51%.
முக்கிய அம்சங்கள்
Proposed addition of approximately 300 beds in Chennai, marking the company's entry into Tamil Nadu.Total project investment estimated at Rs 300 crore to be deployed over 36 months.Funding to be sourced via a combination of bank loans and internal accruals.The land is acquired on a long-term lease from Andhra Mahila Sabha in Raja Annamalai Puram.Existing group capacity stands at 8,800+ beds with 51% occupancy as of H1FY26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the project's execution timeline as this entry into the high-demand Chennai market could significantly boost long-term revenue. The capital expenditure is manageable given the company's scale, but occupancy ramp-up in the new geography will be a key metric to watch.
KIMS Increases Stake in Sunshine Hospital to 75.53% for Rs 148.09 Crore
Krishna Institute of Medical Sciences (KIMS) has increased its equity stake in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital), from 68.59% to 75.53%. The acquisition of the additional 6.94% stake was completed via a secondary cash purchase for approximately Rs 148.09 crore. Sunshine Hospital is a high-performing asset, reporting a turnover of Rs 597 crore in FY25, representing a 28.6% growth over the previous year. This move consolidates KIMS's control over a key revenue-generating entity focused on orthopedics and multi-specialty care.
முக்கிய அம்சங்கள்
Acquired additional 6.94% stake in Sarvejana Healthcare for a cash consideration of Rs 148.09 croreTotal shareholding in the material subsidiary increased to 75.53% from 68.59%Sunshine Hospital turnover grew significantly from Rs 464.20 crore in FY24 to Rs 597.00 crore in FY25The acquisition was executed as a strategic investment through a secondary purchase based on a valuation reportSunshine Hospital specializes in high-end healthcare including orthopedics, cardiology, and transplants
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move to consolidate ownership in a fast-growing and profitable subsidiary. The increased stake will lead to higher profit attribution to KIMS shareholders from the Sunshine Hospital business.
KIMS Commences Operations at 350-Bed Multi-Specialty Hospital in Bengaluru
Krishna Institute of Medical Sciences (KIMS) has officially commenced operations at its new 350-bed multi-specialty tertiary care hospital in Electronic City, Bengaluru, as of December 15, 2025. The facility is operated through its subsidiary, KIMS Hospital Bengaluru Private Limited, and is located within the PES University campus. This expansion significantly strengthens the company's footprint in the Karnataka healthcare market. The hospital will provide advanced services in high-margin specialties including Oncology, Organ Transplant, and Robotic Sciences.
முக்கிய அம்சங்கள்
Commencement of operations at a new 350-bedded multi-specialty hospital on December 15, 2025Strategically located at PES University campus in Electronic City, a major technology hub in BengaluruFocus on high-end tertiary care including Cardiac, Neuro, Oncology, and Organ Transplant servicesExpansion executed through subsidiary KIMS Hospital Bengaluru Private LimitedFacility equipped with 24/7 emergency services and cutting-edge robotic surgery technology
👀 கவனிக்க வேண்டியவை
Investors should monitor the occupancy ramp-up and the impact of gestation costs on near-term margins. This expansion is a long-term value creator that enhances KIMS's competitive positioning in the high-demand Bengaluru market.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
